Where is Progenics located?

Progenics is headquartered in United States. It is registered at New York, New York.

How many employees does Progenics have?

As of Mar 31, 2026, the latest employee count at Progenics is 47.

Is Progenics a funded company?

Progenics is a funded company, having raised an undisclosed amount across 10 funding rounds to date. The company's 1st funding round was a $***** Conventional Debt round.

When was the latest funding round of Progenics?

Progenics' latest funding was a $***** Post IPO round on Jan 18, 2013, with participation from 0 investor.

Where does Progenics rank among its competitors?

Progenics ranks 57th amongst 105 active competitors, of which 29 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Ionetix, which secured an undisclosed amount in Aug, 2024.

Who are the top competitors of Progenics?

Progenics' top competitors include Artera, MDxHealth and AC Immune. Among them, Ionetix secured the most recent funding round in August, 2024.

Progenics - 2026 Company Profile, Funding & Competitors

Company Details

Progenics Pharmaceuticals is developing imaging agents and targeted radiotherapeutics for oncology. Progenics' first-in-class prostate-specific membrane antigen (PSMA)-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic & a small molecule agent (targeted radiotherapy). Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra, an ultra-orphan radiotherapy candidate being developed for the treatment of malignant pheochromocytoma and paraganglioma. Progenics’ first commercial product, Relistor (methylnaltrexone bromide) is approved for the treatment of opioid-induced constipation.

Website: progenics.com
Social
Registered Address: New York, New York

Key Metrics

Founded Year

1988

Location

United States

Stage

Acqui-Hired

Latest Funding Round

Post IPO, Jan 18, 2013, $*****

Investors

HealthCare Royalty Partners & 2 more

Ranked

57^th among 105 active competitors

Employee Count

47 as on Mar 31, 2026

Investment & Acquisitions

AZEDRA & 2 more

Similar Companies

Artera & 133 more

View Progenics' full profile

Progenics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
PROGENICS PHARMACEUTICALS, INC. CIN: 133379479 , United States, Active	Dec 31, 1999	-	53 (As on Dec 31, 2020)	-

Progenics has raised funding over 10 rounds. Progenics has 3 institutional investors.

Here is the list of recent funding rounds of Progenics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 18, 2013	5631351	Post IPO	9943527	9709013	4070725	9950518
May 01, 2011	5138215	Grant (prize money)	8479522	5294442	8113846	HHS
Apr 29, 2011	3447248	Grant (prize money)	8252001	8929126	6136828	HHS

Access funding benchmarks and valuations. Sign up today!

View details of Progenics's funding rounds and investors

Progenics' employee count trend

Progenics has 47 employees as of Mar 26. Here is Progenics's employee count trend over the years:

Uncover Progenics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Progenics include Artera, MDxHealth and AC Immune. Here is the list of Top 10 competitors of Progenics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Artera 2021, Menlo Park (United States), Series A	AI-derived prognostic biomarker test for cancer detection	$135M	Walden Catalyst, Breyer Capital & 23 others	62/100
2nd	MDxHealth 2003, Irvine (United States), Public	Provider of epigenetic tests for personalized cancer assessment and treatment	-	Life Sciences Partners, Kreos Capital & 11 others	62/100
3rd	AC Immune 2003, Lausanne (Switzerland), Public	Developer of antibodies, small molecules, and vaccines for Alzheimer’s disease and other neurodegenerative diseases	$120M	BVF Partners, Redmile Group & 4 others	61/100
4th	Opko Health 1991, Miami (United States), Public	Provider of molecular diagnostic products	-	Oracle, Gates Foundation & 1 others	58/100
5th	ProteoMediX 2010, Schlieren (Switzerland), Acquired	Developer of next-generation blood test for prostate cancer	$17.6M	Venture Kick, Altos Ventures Management & 3 others	56/100
6th	Ionetix 2009, San Francisco (United States), Series C	Radiopharmaceutical solutions provider specializing in cyclotron technology and targeted alpha therapy	$61.1M	Lilly, Riverland Capital & 1 others	56/100
7th	Curium 2017, Paris (France), Seed	Specialty developer, manufacturer & distributor of radiopharmaceuticals	-	CapVest	56/100
8th	RadioMedix 2006, Houston (United States), Series A	Developer of targeted radiopharmaceuticals for cancer diagnosis and treatment	$40M	Military Health, Portland & 1 others	55/100
9th	Niowave 2005, Lansing (United States), Series A	Provider of devices and radioisotopes for nuclear imaging	$9.95M	SBIR, OSTI	53/100
10th	Telix Pharma 2015, Melbourne (Australia), Public	Developer of theranostic radiopharmaceuticals for imaging and treating cancer	-	China Grand Pharmaceutical and Healthcare	52/100
57th	Progenics 1988, United States, Acqui-Hired	Imaging compounds & targeted radiotherapies to detect and treat prostate cancer.	-	HealthCare Royalty Partners, Healthcare Ventures ... & 1 others	33/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Progenics's competitors? Click here to see the top ones

Progenics has acquired 3 companies including AZEDRA, EXINI Diagnostics and Molecular Insight Pharmaceuticals. Progenics has not made any investments as of now.

Here is the list of its acquisitions:

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Feb 11, 2019	Acquisition	AZEDRA	2006	-
Oct 13, 2015	Acquisition	EXINI Diagnostics	1999	Lund (Sweden)
Jan 22, 2013	Acquisition	Molecular Insight Pharmaceuticals	1997	Cambridge (United States)